Safety of withholding heparin in pregnant women with a history of venous thromboembolism

New England Journal of Medicine

Volumn 343, Issue 20, 2000, Pages 1439-1444

  Brill Edwards, Patrick ^a   Ginsberg, Jeffrey S ^a   Gent, Michael ^a   Hirsh, Jack ^a   Burrows, Robert ^b   Kearon, Clive ^a   Geerts, William ^c   Kovacs, Michael ^d   Weitz, Jeffrey I ^a   Robinson, K Susan ^e   Whittom, Renaud ^f   Couture, Ghislaine ^g  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b MONASH MEDICAL CENTRE   (Australia)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^f HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^g LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; RECURRENT DISEASE; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ADULT; ANTICOAGULANTS; BLOOD PROTEINS; FEMALE; HEPARIN; HUMANS; INCIDENCE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL CARE; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0034676551     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200011163432002     Document Type: Article

References (30)

1. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT Study
2. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
3. Inherited thrombophilia
4. Maternal mortality in Massachusetts: Trends and prevention
5. Causes of maternal mortality in the United States
6. Use of antithrombotic agents during pregnancy
7. Guidelines on the prevention, investigation and management of thrombosis associated with pregnancy
8. The British Society for Haematology guidelines on the use and monitoring of heparin 1992: Second revision
9. Recurrent thromboembolism in pregnancy and puerperium: Is there a need for thromboprophylaxis?
10. Recurrence of venous thromboembolic disease and use of oral contraceptives
11. The risks of antenatal subcutaneous heparin prophylaxis: A controlled trial
12. Prophylaxis of thromboembolism in pregnancy: An alternative
13. Low risk of recurrent thromboembolism in pregnancy
14. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin
15. Osteopenia in pregnancy during long-term heparin treatment: A radiological study post partum
16. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism
17. Detection of deep-vein thrombosis by real-time B-mode ultrasonography
18. Mutation in blood coagulation factor V associated with resistance to activated protein C
19. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
20. Fast functional protein C assay using Protac, a novel protein C activator
21. Two ELISA's for measurement of protein S, and their use in the laboratory diagnosis of protein S deficiency
22. New chromogenic AT III activity kit which is insensitive to heparin cofactor II and designed for use on automated instruments
23. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardization and quantification of results
24. The partial thromboplastin time with kaolin: A simple screening test for first stage plasma clotting factor deficiencies
25. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification
26. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants
27. Changes in protein C and protein S levels in normal pregnancy
28. Changes in protein C and free protein S during pregnancy and following hysterectomy
29. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
30. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis